PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2–advanced breast cancer (BC): first results from the randomized, phase III BELLE‑2 trial. San Antonio Breast Cancer Symposium - Baselga, J; Im, S A; Iwata, H (San Antonio, TX, USA; Abstract, 2015)
et al.